Does the media refer more to RYTM or VIR?

In the previous week, Vir Biotechnology had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Vir Biotechnology and 4 mentions for Rhythm Pharmaceuticals. Vir Biotechnology's average media sentiment score of 0.34 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VIR or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Vir Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Vir Biotechnology N/A -29.99% -23.62% Oruka Therapeutics N/A -21.65% -20.88%

Does the media refer more to VIR or ORKA?

In the previous week, Vir Biotechnology had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 9 mentions for Vir Biotechnology and 4 mentions for Oruka Therapeutics. Vir Biotechnology's average media sentiment score of 0.34 beat Oruka Therapeutics' score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MIRM or VIR?

In the previous week, Mirum Pharmaceuticals had 26 more articles in the media than Vir Biotechnology. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 9 mentions for Vir Biotechnology. Mirum Pharmaceuticals' average media sentiment score of 0.58 beat Vir Biotechnology's score of 0.34 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vir Biotechnology (VIR) Competitors

$11.17 -0.12 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$11.00 -0.17 (-1.52%)

As of 07:38 PM Eastern

Compare

VIR vs. RYTM, CGON, ORKA, KNSA, and MIRM

Should you buy Vir Biotechnology stock or one of its competitors? Vir Biotechnology's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), CG Oncology (CGON), Oruka Therapeutics (ORKA), Kiniksa Pharmaceuticals International (KNSA), and Mirum Pharmaceuticals (MIRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vir Biotechnology compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Rhythm Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	26.52	-$196.54M	-$3.11	N/A
Vir Biotechnology	$68.56M	27.57	-$437.99M	-$1.86	N/A

Rhythm Pharmaceuticals has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus price target of $140.67, indicating a potential upside of 51.53%. Vir Biotechnology has a consensus price target of $21.57, indicating a potential upside of 93.12%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Vir Biotechnology has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Vir Biotechnology's return on equity of -29.99% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Vir Biotechnology	N/A	-29.99%	-23.62%

65.3% of Vir Biotechnology shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vir Biotechnology had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Vir Biotechnology and 4 mentions for Rhythm Pharmaceuticals. Vir Biotechnology's average media sentiment score of 0.34 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vir Biotechnology beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

CG Oncology currently has a consensus price target of $87.78, indicating a potential upside of 30.27%. Vir Biotechnology has a consensus price target of $21.57, indicating a potential upside of 93.12%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

CG Oncology has higher earnings, but lower revenue than Vir Biotechnology. CG Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,478.36	-$160.99M	-$2.69	N/A
Vir Biotechnology	$68.56M	27.57	-$437.99M	-$1.86	N/A

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vir Biotechnology has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Vir Biotechnology	N/A	-29.99%	-23.62%

CG Oncology has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

In the previous week, Vir Biotechnology had 9 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Vir Biotechnology and 0 mentions for CG Oncology. Vir Biotechnology's average media sentiment score of 0.34 beat CG Oncology's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
CG Oncology	Neutral
Vir Biotechnology	Neutral

Summary

Vir Biotechnology beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Oruka Therapeutics?

Vir Biotechnology (NASDAQ:VIR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Vir Biotechnology has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market.

Oruka Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	27.57	-$437.99M	-$1.86	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Vir Biotechnology currently has a consensus price target of $21.57, indicating a potential upside of 93.12%. Oruka Therapeutics has a consensus price target of $128.91, indicating a potential upside of 52.52%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics' return on equity of -21.65% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, Vir Biotechnology had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 9 mentions for Vir Biotechnology and 4 mentions for Oruka Therapeutics. Vir Biotechnology's average media sentiment score of 0.34 beat Oruka Therapeutics' score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Vir Biotechnology beats Oruka Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Vir Biotechnology compare to Kiniksa Pharmaceuticals International?

Vir Biotechnology (NASDAQ:VIR) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Vir Biotechnology presently has a consensus price target of $21.57, indicating a potential upside of 93.12%. Kiniksa Pharmaceuticals International has a consensus price target of $93.14, indicating a potential upside of 22.90%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Vir Biotechnology is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Vir Biotechnology has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	27.57	-$437.99M	-$1.86	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.73	$59.01M	$0.97	78.13

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Vir Biotechnology's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

In the previous week, Vir Biotechnology had 5 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 9 mentions for Vir Biotechnology and 4 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.66 beat Vir Biotechnology's score of 0.34 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Vir Biotechnology on 10 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

65.3% of Vir Biotechnology shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus target price of $142.56, suggesting a potential upside of 71.91%. Vir Biotechnology has a consensus target price of $21.57, suggesting a potential upside of 93.12%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Mirum Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.33	-$23.36M	-$14.55	N/A
Vir Biotechnology	$68.56M	27.57	-$437.99M	-$1.86	N/A

In the previous week, Mirum Pharmaceuticals had 26 more articles in the media than Vir Biotechnology. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 9 mentions for Vir Biotechnology. Mirum Pharmaceuticals' average media sentiment score of 0.58 beat Vir Biotechnology's score of 0.34 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vir Biotechnology has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Vir Biotechnology's return on equity of -29.99% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Vir Biotechnology	N/A	-29.99%	-23.62%

Summary

Mirum Pharmaceuticals beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.91B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.77%
P/E Ratio	-6.01	12.93	273.67	26.04
Price / Sales	27.57	1,277.15	602.53	86.50
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	2.03	16.63	10.92	6.30
Net Income	-$437.99M	-$22.67M	$3.50B	$361.43M
7 Day Performance	4.78%	-3.05%	-2.11%	-1.67%
1 Month Performance	-2.87%	-10.75%	-6.34%	-3.94%
1 Year Performance	97.35%	21.11%	8.81%	2.77%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	2.5708 of 5 stars	$11.17 -1.1%	$21.57 +93.1%	+98.1%	$1.91B	$68.56M	N/A	367	News Coverage Gap Up
RYTM Rhythm Pharmaceuticals	2.6882 of 5 stars	$98.83 +1.1%	$140.67 +42.3%	-6.6%	$6.70B	$189.76M	N/A	414
CGON CG Oncology	2.3127 of 5 stars	$78.25 +4.9%	$87.78 +12.2%	+73.2%	$6.61B	$4.04M	N/A	142
ORKA Oruka Therapeutics	2.2499 of 5 stars	$93.38 -1.7%	$133.00 +42.4%	+348.0%	$6.29B	N/A	N/A	68	Insider Trade
KNSA Kiniksa Pharmaceuticals International	4.2753 of 5 stars	$78.13 +1.2%	$87.38 +11.8%	+94.7%	$6.03B	$677.56M	80.55	366	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. RYTM, CGON, ORKA, KNSA, and MIRM

How does Vir Biotechnology compare to Rhythm Pharmaceuticals?

Summary

How does Vir Biotechnology compare to CG Oncology?

Summary

How does Vir Biotechnology compare to Oruka Therapeutics?

Summary

How does Vir Biotechnology compare to Kiniksa Pharmaceuticals International?

Summary

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. RYTM, CGON, ORKA, KNSA, and MIRM

How does Vir Biotechnology compare to Rhythm Pharmaceuticals?

Which has better earnings and valuation, RYTM or VIR?

Which has more risk & volatility, RYTM or VIR?

Do analysts recommend RYTM or VIR?

Is RYTM or VIR more profitable?

Do insiders & institutionals believe in RYTM or VIR?

Does the media refer more to RYTM or VIR?

Summary

How does Vir Biotechnology compare to CG Oncology?

Do analysts rate CGON or VIR?

Which has higher valuation & earnings, CGON or VIR?

Do insiders & institutionals believe in CGON or VIR?

Is CGON or VIR more profitable?

Which has more volatility & risk, CGON or VIR?

Does the media prefer CGON or VIR?

Summary

How does Vir Biotechnology compare to Oruka Therapeutics?

Which has more risk and volatility, VIR or ORKA?

Which has preferable earnings & valuation, VIR or ORKA?

Do analysts recommend VIR or ORKA?

Is VIR or ORKA more profitable?

Does the media refer more to VIR or ORKA?

Do institutionals and insiders have more ownership in VIR or ORKA?

Summary

How does Vir Biotechnology compare to Kiniksa Pharmaceuticals International?

Do analysts prefer VIR or KNSA?

Which has more risk and volatility, VIR or KNSA?

Do institutionals and insiders have more ownership in VIR or KNSA?

Which has higher valuation and earnings, VIR or KNSA?

Is VIR or KNSA more profitable?

Does the media prefer VIR or KNSA?

Summary

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Do institutionals & insiders believe in MIRM or VIR?

Do analysts rate MIRM or VIR?

Which has more volatility and risk, MIRM or VIR?

Which has better valuation & earnings, MIRM or VIR?

Does the media favor MIRM or VIR?

Is MIRM or VIR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools